company background image
A950210 logo

Prestige BioPharma KOSE:A950210 Stock Report

Last Price

₩15.10k

Market Cap

₩171.6b

7D

8.0%

1Y

49.2%

Updated

04 Oct, 2024

Data

Company Financials

Prestige BioPharma Limited

KOSE:A950210 Stock Report

Market Cap: ₩171.6b

A950210 Stock Overview

A biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines.

A950210 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Prestige BioPharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prestige BioPharma
Historical stock prices
Current Share Price₩15,100.00
52 Week High₩16,220.00
52 Week Low₩7,610.00
Beta1.19
11 Month Change10.22%
3 Month Change64.31%
1 Year Change49.21%
33 Year Change-42.80%
5 Year Changen/a
Change since IPO-53.96%

Recent News & Updates

Recent updates

Shareholder Returns

A950210KR BiotechsKR Market
7D8.0%-3.9%-3.9%
1Y49.2%45.5%4.8%

Return vs Industry: A950210 exceeded the KR Biotechs industry which returned 45.5% over the past year.

Return vs Market: A950210 exceeded the KR Market which returned 4.8% over the past year.

Price Volatility

Is A950210's price volatile compared to industry and market?
A950210 volatility
A950210 Average Weekly Movement10.6%
Biotechs Industry Average Movement9.4%
Market Average Movement6.8%
10% most volatile stocks in KR Market12.1%
10% least volatile stocks in KR Market3.5%

Stable Share Price: A950210's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A950210's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2015n/aSo-Yeon Parkwww.prestigebiopharma.com

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor.

Prestige BioPharma Limited Fundamentals Summary

How do Prestige BioPharma's earnings and revenue compare to its market cap?
A950210 fundamental statistics
Market cap₩171.63b
Earnings (TTM)-₩32.92b
Revenue (TTM)₩689.08m

263.4x

P/S Ratio

-5.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A950210 income statement (TTM)
Revenue₩689.08m
Cost of Revenue₩1.22b
Gross Profit-₩528.79m
Other Expenses₩32.39b
Earnings-₩32.92b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.74k
Gross Margin-76.74%
Net Profit Margin-4,777.60%
Debt/Equity Ratio20.1%

How did A950210 perform over the long term?

See historical performance and comparison